Kyle Gano

Kyle Gano, listed as chief executive, appears in our data through filings on Neurocrine Biosciences Inc shares, published by SEC (Form 4). Between 11 January 2016 and 11 September 2026, the trades on record add up to 24 filings.

Sales make up the whole of the open-market record (10 sales, €1.2M). No amount is published for 3 filings, which the totals therefore leave out. Besides market trades, the filings include 4 share grants and 10 option exercises.

On 15 September 2026 came the latest disclosure, a share grant in Neurocrine Biosciences Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.